We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (NASDAQ:RDEA) with a target price of $20. Ardea Biosciences, headquartered in San Diego, CA, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV) and cancer. Ardea recently reported disappointing second quarter 2010 results. The development stage biopharmaceutical company’s ...